Xeris Biopharma Holdings Inc (0A8E.L)

Healthcare | Biotechnology
Income Statement (Quarterly) 2025-06-30 2025-03-31 2024-12-31 2024-12-31
Revenue 71,539,000 60,119,000 60,099,000 60,099,000
Cost of Revenue 14,609,000 8,728,000 9,478,000 0
Gross Profit 56,930,000 51,391,000 50,621,000 60,099,000
Operating Expenses
R&D Expenses 0 0 0 0
SG&A Expenses 44,393,000 44,018,000 40,139,000 40,139,000
Operating Expenses 52,448,000 54,481,000 48,942,000 46,231,000
Operating Income 4,482,000 -3,090,000 1,679,000 1,679,000
Interest Expense 7,358,000 7,305,000 7,703,000 0
Income Before Tax -1,928,000 -9,220,000 -5,113,000 -5,113,000
Income Tax Expense 0 0 0 0
Net Income -1,928,000 -9,220,000 -5,113,000 -5,113,000
Per Share
EPS -0.01 -0.06 -0.03 -0.03
EPS Diluted 0.00 0.00 0.00 0.00
Income Statement (Annual) 2024-12-31 2023-12-31 2022-12-31
Revenue 203,070,000 163,914,000 110,248,000
Cost of Revenue 36,832,000 28,645,000 22,634,000
Gross Profit 166,238,000 135,269,000 87,614,000
Operating Expenses
R&D Expenses 0 0 0
SG&A Expenses 163,481,000 146,095,000 137,745,000
Operating Expenses 199,884,000 179,279,000 169,554,000
Operating Income -33,646,000 -44,010,000 -81,940,000
Interest Expense 33,175,000 26,609,000 15,325,000
Income Before Tax -57,104,000 -63,504,000 -96,084,000
Income Tax Expense -2,268,000 -1,249,000 -1,424,000
Net Income -54,836,000 -62,255,000 -94,660,000
Per Share
EPS -0.37 -0.45 -0.70
EPS Diluted 0.00 0.00 0.00
Balance Sheet (Quarterly) 2024-12-31 2023-12-31 2022-12-31
Assets
Cash and Cash Equivalents 71,621,000 67,449,000 121,966,000
Short Term Investments 0 5,002,000 0
Net Receivables 40,415,000 39,197,000 30,830,000
Inventory 48,175,000 38,838,000 24,735,000
Total Current Assets 167,662,000 156,264,000 186,818,000
Property Plant Equipment 28,211,000 29,175,000 28,375,000
Goodwill and Intangibles 121,780,000 132,623,000 124,599,000
Total Assets 323,060,000 322,602,000 344,522,000
Liabilities
Account Payables 2,290,000 11,565,000 4,606,000
Short Term Debt 21,182,000 3,495,000 1,580,000
Total Current Liabilities 100,443,000 95,193,000 73,621,000
Long Term Debt 250,265,000 225,696,000 196,477,000
Total Liabilities 352,675,000 329,384,000 299,335,000
Shareholders Equity
Retained Earnings -671,861,000 -617,025,000 -554,770,000
Total Shareholders Equity -29,615,000 -6,782,000 45,187,000
Balance Sheet (Annual) 2024-12-31 2023-12-31 2022-12-31
Assets
Cash and Cash Equivalents 71,621,000 67,449,000 121,966,000
Short Term Investments 0 5,002,000 0
Net Receivables 40,415,000 39,197,000 30,830,000
Inventory 48,175,000 38,838,000 24,735,000
Total Current Assets 167,662,000 156,264,000 186,818,000
Property Plant Equipment 28,211,000 29,175,000 28,375,000
Goodwill and Intangibles 121,780,000 132,623,000 124,599,000
Total Assets 323,060,000 322,602,000 344,522,000
Liabilities
Account Payables 2,290,000 11,565,000 4,606,000
Short Term Debt 21,182,000 3,495,000 1,580,000
Total Current Liabilities 100,443,000 95,193,000 73,621,000
Long Term Debt 250,265,000 225,696,000 196,477,000
Total Liabilities 352,675,000 329,384,000 299,335,000
Shareholders Equity
Retained Earnings -671,861,000 -617,025,000 -554,770,000
Total Shareholders Equity -29,615,000 -6,782,000 45,187,000
Cash Flow Statement (Quarterly) 2024-12-31 2023-12-31 2022-12-31
Operating Activities
Net Income -54,836,000 -62,255,000 -94,660,000
Depreciation & Amortization 12,625,000 13,160,000 12,668,000
Stock Based Compensation 18,363,000 10,716,000 12,160,000
Change in Working Capital -8,820,000 -6,294,000 -35,150,000
Operating Cash Flow -36,981,000 -47,023,000 -102,891,000
Investing Activities
Capital Expenditure -868,000 -2,263,000 -524,000
Investments -868,000 -2,263,000 -524,000
Investing Cash Flow 4,883,000 -6,004,000 34,461,000
Financing Activities
Debt Repayment 38,169,000 0 102,718,000
Common Stock Issued/Repurchased -3,734,000 -1,009,000 29,532,000
Dividends Paid 0 0 0
Financing Cash Flow 36,168,000 -1,613,000 127,473,000
Summary
Free Cash Flow -37,849,000 -49,286,000 -103,415,000
Net Change in Cash 4,070,000 -54,640,000 59,043,000
Cash Flow Statement (Annual) 2024-12-31 2023-12-31 2022-12-31
Operating Activities
Net Income -54,836,000 -62,255,000 -94,660,000
Depreciation & Amortization 12,625,000 13,160,000 12,668,000
Stock Based Compensation 18,363,000 10,716,000 12,160,000
Change in Working Capital -8,820,000 -6,294,000 -35,150,000
Operating Cash Flow -36,981,000 -47,023,000 -102,891,000
Investing Activities
Capital Expenditure -868,000 -2,263,000 -524,000
Investments -868,000 -2,263,000 -524,000
Investing Cash Flow 4,883,000 -6,004,000 34,461,000
Financing Activities
Debt Repayment 38,169,000 0 102,718,000
Common Stock Issued/Repurchased -3,734,000 -1,009,000 29,532,000
Dividends Paid 0 0 0
Financing Cash Flow 36,168,000 -1,613,000 127,473,000
Summary
Free Cash Flow -37,849,000 -49,286,000 -103,415,000
Net Change in Cash 4,070,000 -54,640,000 59,043,000